These results align with the work of Ma et al. (2008) [37], who reported that increased ezrin expression was positively correlated with lymph node involvement, indicating that ezrin may serve as a biomarker for predicting lymphatic metastasis in breast carcinoma. Here, EZR is linked to breast carcinoma.